The Securities and Exchange Commission suspended trading in shares of Vaso Active Pharmaceuticals ( VAPH), the Nasdaq company that claims to have developed a revolutionary treatment for athlete's foot.

The action followed a series of articles on questioning the company's statements about its clinical trials and medical endorsements and noting troubling aspects of its corporate pedigree.

"The commission temporarily suspended trading in the securities of VAPH because of questions regarding the accuracy of assertions by VAPH and by others, in press releases, its annual report, its registration statement and public statements to investors concerning, among other things: FDA approval of certain key products, and the regulatory consequences of the future application of their primary product," a press release from the SEC read.

"The commission cautions broker dealers, shareholders and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by the company," it said.